These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 30516990)

  • 41. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.
    Maddocks S; Dwyer D
    Paediatr Drugs; 2001; 3(9):681-702. PubMed ID: 11688599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Corbett JW; Rodgers JD
    Prog Med Chem; 2002; 40():63-105. PubMed ID: 12516523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
    Thammaporn R; Ishii K; Yagi-Utsumi M; Uchiyama S; Hannongbua S; Kato K
    Biol Pharm Bull; 2016; 39(3):450-4. PubMed ID: 26934936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
    Vanangamudi M; Palaniappan S; Kathiravan MK; Namasivayam V
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dipyridodiazepinone analogs as human immunodeficiency virus type 1-specific non-nucleoside reverse transcriptase inhibitors: an overview.
    Lv M; Xu H
    Curr Med Chem; 2010; 17(18):1874-98. PubMed ID: 20377515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.
    Camarasa MJ; San-Félix A; Velázquez S; Pérez-Pérez MJ; Gago F; Balzarini J
    Curr Top Med Chem; 2004; 4(9):945-63. PubMed ID: 15134550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging anti-HIV drugs.
    De Clercq E
    Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.
    Chen X; Zhan P; Li D; De Clercq E; Liu X
    Curr Med Chem; 2011; 18(3):359-76. PubMed ID: 21143120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.